Fingerprint
Dive into the research topics of 'SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
SAPPHIRE Investigators
- IRCCS Istituto Europeo di Oncologia - Milano
- Erasmus University Rotterdam
- Florida Cancer Specialists and Research Institute – South Region (SCRI)
- Netherlands Cancer Institute
- Hospital Regional Universitario Carlos Haya
- Sarah Cannon Research Institute
- Paoli-Institut Calmettes
- University of California at Los Angeles
- Ohio State University
- Université Paris-Sud
- German Center for Lung Research
- Royal Marsden NHS Foundation Trust
- Yale University
- Emory University
- Mirati Therapeutics
- University of Lausanne
Research output: Contribution to journal › Article › peer-review
57
Scopus
citations